Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tom van Cann"'
Publikováno v:
Oncology Research and Treatment. 41:214-219
Background: The treatment of advanced desmoid-type fibromatosis (DF) is poorly standardized and primarily based on physician's choice. We assessed systemic treatment preferences for advanced DF among European experts, with the aim to define a control
Autor:
Jasmien Cornillie, Agnieszka Wozniak, Patrick Schöffski, Tom van Cann, Daphne Hompes, Raf Sciot, Ignace Vergote, Maria Debiec-Rychter
Publikováno v:
Oncology Research and Treatment. 41:206-213
Background: Leiomyosarcoma is a common subtype of soft tissue sarcoma originating from smooth muscle. We evaluated the clinical course and treatment outcome of patients with metastatic leiomyosarcoma. Methods: We retrospectively reviewed the records
Autor:
Raf Vandeweyer, Tom van Cann, Paul Clement, Oliver Bechter, Herlinde Dumez, Patrick Schöffski, Isabel Spriet, Tine Loyson, Patrick Neven, Joseph Schoenaers, Kristiaan Nackaerts, Hans Wildiers, Constantinus Politis, Patrick Berteloot, Ruxandra-Gabriela Coropciuc, Kevin Punie, F. J. S. H. Woei-A-Jin, Benoit Beuselinck
Publikováno v:
Acta Clinica Belgica. 73:100-109
Osteonecrosis of the jaw (ONJ) is a serious adverse event of bone resorption inhibitors (BRIs), such as bisphosphonates and denosumab. Bisphosphonates and denosumab inhibit osteoclast function through different pharmacological effects and bisphosphon
Autor:
Tom van Cann, Judith V.M.G. Bovée, Inti Zlobec, Raf Sciot, Jasmien Wellens, Patrick Schöffski, Christian Britschgi, Che-Jui Lee, Agnieszka Wozniak
Publikováno v:
Journal of Global Oncology. 5:38-38
38 Background: STS is a very heterogeneous family of orphan malignancies, characterized by morphological and genetic diversity. Tissue samples from individual STS patients are commonly used for routine diagnostic and research purposes. TMAs from mult